CTOs on the Move

IntelGenx

www.intelgenx.com

 
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.intelgenx.com
  • 6420 Rue Abrams
    Saint-Laurent, QC CAN H4S 1Y2
  • Phone: 514.331.7440

Executives

Name Title Contact Details

Similar Companies

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

AstraZeneca Pharmaceuticals LP

AstraZeneca Pharmaceuticals LP is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.